Publications by authors named "Matthias Paland"
Article Synopsis
- - The ADRISK trial is a study focused on patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are at high risk of recurrence after surgery.
- - It compares the effectiveness of standard adjuvant radio(chemo)therapy (aRCT) with cisplatin to aRCT combined with pembrolizumab, an immunotherapy drug, in improving event-free survival.
- - The trial involves 240 patients with specific criteria and aims to assess outcomes in terms of event-free and overall survival, with recruitment commencing in August 2018 and still ongoing.
Treatment of cancer patients has become challenging when large parts of hospital services need to be shut down as a consequence of a local COVID-19 outbreak that requires rapid containment measures, in conjunction with the shifting of priorities to vital services. Reports providing conceptual frameworks and first experiences on how to maintain a clinical hematology/oncology service during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are scarce. Here, we report our first 8 weeks of experience after implementing a procedural plan at a hematology/oncology unit with its associated cancer center at a large academic teaching hospital in Germany.
View Article and Find Full Text PDFHigh carriage rate of ESBL-producing Enterobacteriaceae at presentation and follow-up among travellers with gastrointestinal complaints returning from India and Southeast Asia.
J Travel Med
February 2016
Background: International travel contributes to the spread of multidrug-resistant microorganisms including extended spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE). We assessed the proportion of faecal carriers of ESBL-PE among 211 patients with gastrointestinal symptoms who returned to Berlin, Germany, after international travel.
Methods: ESBL-PE were screened for on chromogenic agar, antimicrobial susceptibility testing was performed, and ESBL-genes were genotyped.